Home > Neurology > ECTRIMS 2018 > Letter from the Editor

Letter from the Editor

Professor Hans-Peter Hartung, University of Düsseldorf, Germany
Dear Reader, Almost 10,000 neurologists, researchers, and MS professionals attended the ECTRIMS 2018 in Berlin, to get updates on the new developments regarding diagnosis, treatment, pathology, and biomarker research. The revised 2017 McDonald diagnostic criteria continue to be validated, but their use in routine practice has several implications. Data on safety and efficacy of both novel and established biological agents are driving forward the treatment of both relapsing and progressive MS. Interesting data on head-to-head comparison of DMTs was also presented. In addition, knowing which patients to treat with which DMT, and when to discontinue or switch is of key importance and was investigated in several cohort studies. An important topic was the undertreatment of MS symptoms such as cognitive dysfunction, affecting quality of life. An observational study suggested a neuroprotective effect of vitamin D supplementation. Major advances are still being ma...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on